Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

February 29, 2016

Study Completion Date

April 30, 2017

Conditions
Multiple Myeloma
Interventions
DRUG

Panobinostat

"Panobinostat will be supplied as 5-mg or 20-mg pink/opaque-colored, hard gelatin capsules. Panobinostat is administered orally three times per week.~* Standard 3+3 design~* 3 out of 4 weeks"

DRUG

Carfilzomib

"Carfilzomib in Cycle 1 will be initiated intravenously at 20 mg/m² on Days 1 and 2 and escalated to 27 mg/m² for Days 8, 9, 15, and 16 of Cycle 1 and for the duration of treatment.~* Standard 3+3 design~* Days 1/2, 8/9 and 15/16 every 4 weeks"

DRUG

Dexamethasone

Dexamethasone (4 mg) must be given prior to each carfilzomib infusion during Cycle 1. Dexamethasone pre-dose should continue through Cycle 2 if fever is observed post-dose, Cycle 2 Day 1, or thereafter associated with the infusion of carfilzomib.

Trial Locations (3)

30322

Emory University Winship Cancer Institute, Atlanta

60637

University of Chicago, Chicago

94115

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

Sponsors
All Listed Sponsors
lead

Emory University

OTHER

collaborator

Multiple Myeloma Research Consortium

NETWORK

collaborator

Novartis

INDUSTRY

collaborator

Onyx Therapeutics, Inc.

INDUSTRY

collaborator

Amgen

INDUSTRY

collaborator

University of California, San Francisco

OTHER

collaborator

University of Chicago

OTHER